Ionis Pharmaceuticals Overview
Ionis Pharmaceuticals Target Price
Analysts' 12-month price predictions for IONS.
Share Price
$43.24
Average Target Price
Analyst Recommendations
No recommendations in the last 4 months.
Revenue & Income Forecast
Analysts' Target Prices
| Date | Analyst | Price Target | Current Upside/Downside | |
|---|---|---|---|---|
| 2024-10-09 | GuggenheimDebjit Chattopadhyay | $65 |  50.3% upside |  |
| 2024-08-02 | BMO CapitalKostas Biliouris | $60 | 38.8% upside | |
| 2024-07-24 | Leerink PartnersMani Foroohar | $62 | 43.4% upside | |
| 2024-07-22 | JefferiesAkash Tewari | $77 | 78.1% upside | |
| 2024-07-22 | Goldman SachsSalveen Richter | $33 |  23.7% downside | |
| 2024-07-16 | JefferiesAkash Tewari | $75 | 73.5% upside | |
| 2024-06-27 | Stifel NicolausPaul Matteis | $53 | 22.6% upside | |
| 2024-06-17 | RBC CapitalLuca Issi | $70 | 61.9% upside | |
| 2024-06-14 | Tudor PickeringWilliam Pickering | $44 | 1.8% upside | |
| 2024-05-17 | BMO CapitalKostas Biliouris | $67 | 54.9% upside | |
| 2023-02-03 | Leerink Partners | $34 | 21.4% downside | |
| 2022-12-21 | Morgan Stanley | $40 | 7.5% downside | |
| 2022-08-10 | Citigroup | $28 | 35.2% downside | |
| 2022-08-10 | RBC Capital | $64 | 48% upside | |
| 2022-06-21 | Piper SandlerDo Kim | $55 | 27.2% upside | |
| 2022-06-21 | Leerink Partners | $27 | 37.6% downside | |
| 2022-05-09 | Morgan Stanley | $30 | 30.6% downside | |
| 2022-02-24 | NeedhamJoseph Stringer | $60 | 38.8% upside | |
| 2022-02-24 | RBC CapitalLuca Issi | $67 | 54.9% upside | |
| 2022-02-01 | Bank of America SecuritiesJason Gerberry | $30 | 30.6% downside | |
| 2021-11-04 | BarclaysGena Wang | $33 | 23.7% downside | |
| 2021-10-18 | LaidlawYale Jen | $68 | 57.3% upside | |
| 2021-05-10 | UBSEsther Rajavelu | $37.5 | 13.3% downside | |
| 2021-05-05 | OppenheimerKevin DeGeeter | $63 | 45.7% upside | |